Dr Gerald Mboowa
| Call | Career Development Fellowship (CDF) |
| Programme | EDCTP2 |
| Start Date | 2021-11-01 |
| End Date | 2024-10-31 |
| Project Code | TMA2020CDF-3159 |
| Status | Active |
Title
Pathogen detection in HIV-infected children and adolescents with non-malarial febrile illnesses using metagenomic next-generation sequencing approach in Uganda
Host Organisation
| Institution | Country |
|---|---|
Current Organisation
INFECTIOUS DISEASES INSTITUTE
Current Job Title
Scientist
Awards
| 2021 | Training & Mobility Action (TMA) |
Students Supervised
| Type | Name | Title | University | Start Date | End Date |
|---|---|---|---|---|---|
| 2 | Gerald Mboowa | Makerere University | 2021 | 2023 |
Memberships
| Role | Committee/board | Start Date | End Date |
|---|---|---|---|
| Associate Editor | BMC Infectious Diseases | 2020 | |
| Academic Editor | Global Health, Epidemiology and Genomics | 2021 |
Education
| Institution | Degree | Year |
|---|---|---|
| Makerere University, Uganda | PhD | 2020-01-14 |
Areas Of Specialisation
Tuberculosis (TB) Lower Respiratory Tract Infections (LRTIs) Diarrhoeal Diseases (DDs)
Grants
Publications
Authors:
Gerald Mboowa
, Mboowa G. Reviewing the journey to the clinical application of bacteriophages to treat multi-drug-resistant bacteria. BMC Infect Dis. 2023 Oct 3;23(1):654. doi: 10.1186/s12879-023-08621-1. PMID: 37789281; PMCID: PMC10548642.
Date:
2023-10-05
Journal:
BMC Infectious Diseases
Content:
Antimicrobial resistance (AMR) was a leading cause of death globally in 2019. Sadly, COVID-19 has exacerbated AMR, nonetheless, the process of developing new antibiotics remains very challenging. This urgently requires the adoption of alternative approaches to treat multi-drug-resistant bacterial infections. This editorial introduces the ‘Bacteriophages against multi-drug resistant bacteria’ collection launched at BMC Infectious Diseases which highlights progress towards using bacteriophages to tackle AMR
Authors:
Date:
2023-04-21
Journal:
Immunogenetics
Content:
In modern medicine, vaccination is one of the most effective public health strategies to prevent infectious diseases. Indisput- ably, vaccines have saved millions of lives by reducing the burden of many serious infections such as polio, tuberculosis, measles, pneumonia, and tetanus. Despite the recent recommendation by the World Health Organization (WHO) to roll out RTS,S/AS01, this malaria vaccine still faces major challenges of variability in its efficacy partly due to high genetic variation in humans and malaria parasites. Immune responses to malaria vary between individuals and populations. Human genetic variation in immune system genes is the probable cause for this heterogeneity. In this review, we will focus on human genetic factors that determine variable responses to vaccination and how variation in immune system genes affect the immunogenic- ity and efficacy of the RTS,S/AS01 vaccine.